Evaxion Biotech AS (US: EVAX) — Healthcare · Share Price, Chart & Market Data
About: Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.03 (-5.18%)
EVAXEvaxion Biotech AS
Loading watchlist status…
Trade EVAX now
Evaxion Biotech AS share price
EVAX price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 11:02 am GMT+0
EVAX price performance
-10.444%
5D
14.489%
1M
-14.437%
YTD
144.242%
1Y
EVAX price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
US rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 11:02 am GMT+0
EVAX details
EVAX Market Signals